Proteus Digital Health, Inc., the leading digital medicines company, today announced that it has completed a second closing of its Series G financing, raising over $172 million and adding additional respected institutional investors. This latest round of growth equity, one of the largest U.S. private financings this year and the largest in the digital health sector, solidifies Proteus' leadership in digital health.

The company announced on June 2 the first part of this funding series with $120 million from new major institutional investors based in the United States, Europe and Asia. The funding will enable the company to advance the manufacturing and commercialization of digital medicines.

Andrew Thompson, President and Chief Executive Officer of Proteus Digital Health„¢, said, 'The digital health market is rapidly forming. Investor confidence in Proteus is driven by customer excitement, our superior board and leadership team and a unique technology platform that enables us to link one of the most valuable industries of the 20th century ' pharmaceuticals ' to the most important utility of the 21st: the mobile internet.'

Proteus Digital Health„¢ is creating a new category of products, services and data systems that have the potential to significantly improve the effectiveness of existing pharmaceutical treatments. Called digital medicines, these new pharmaceuticals integrate medicines with ingestible, wearable, mobile and cloud computing and deliver solutions that enable patients, their families and physicians to make better decisions about health.

About Proteus Digital Health„¢

Proteus Digital Health„¢ is pioneering a new category of products, services and data systems based on integrating medicines with ingestible, wearable, mobile and cloud computing. Its core technology ' the digital health feedback system ' provides an unprecedented view into an individual's personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians, while enabling new information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and Ingestible Sensor„¢ devices. Headquartered in Redwood City, Calif., Proteus is privately held and funded by Carlyle, Essex Woodlands, Kaiser Permanente, Medtronic, Novartis, Otsuka, Oracle, ON Semiconductor and other investors. Further information is available at: www.proteus.com